PDF factsheet
      Z

antiplatelets drug in cardiovascular prevention for secondary prevention, clinical trials results

clopidogrel versus aspirin
CAPRIE, 1996
clopidogrel 75 mg once daily
versus
aspirin 325 mg once daily
patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial diseaseDouble blind
Follow-up duration: mean 1.91 years
16 countries
clopidogrel versus placebo (on top aspirin)
CHARISMA, 2006
NCT00050817
clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day)
versus
placebo plus low-dose aspirin
patients with either clinically evident cardiovascular disease or multiple risk factorsDouble blind
Follow-up duration: median 28 months
32 countries
ticagrelor versus placebo (on top aspirin)
PEGASUS 60mg, 2015
NCT01225562
ticagrelor at a dose of 60 mg twice daily
versus
placebo
patients who had had a myocardial infarction 1 to 3 years earlierdouble-blind
Follow-up duration: 2.75 y (median)
PEGASUS 90mg, 2015
NCT01225562
ticagrelor at a dose of 90 mg twice daily
versus
patients who had had a myocardial infarction 1 to 3 years earlier double-blind
Follow-up duration: 2.75 y (median)
vorapaxar versus placebo (on top aspirin)
TRA-2P TIMI 50, 2012
NCT00526474
vorapaxar (SCH 530348) 2.5-mg daily
versus
placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel)
patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease)double-blind
Follow-up duration: 2.5 y (median)
TRA-2P TIMI 50 (no prior stroke sub group), 2012
vorapaxar (SCH 530348) 2.5-mg daily
versus
placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel)
patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease), sub group of patient with no prior stroke double-blind
Follow-up duration: 2.5 y (median)
TRA-2P TIMI 50 (MI subgroup), 2012
NCT00526474
vorapaxar (SCH 530348) 2.5-mg daily
versus
placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel)
prespecified subgroup of patients with a qualifying myocardial infarction among the overall population of patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease) double-blind
Follow-up duration: 2.5 y (median)
multinational

  Options


in first

in second

  Filter